Nina Tunariu

List of Publications by Year in descending order

88 papers	11,324 citations	81900 39 h-index	58581 82 g-index
89 all docs	89 docs citations	89 times ranked	15827 citing authors

#	Article	IF	Citations
1	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. Cancer Research, 2022, 81, 1087-1100.	0.9	23
2	Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. European Radiology, 2022, , 1.	4.5	8
3	A review on the added value of whole-body MRI in metastatic lobular breast cancer. European Radiology, 2022, 32, 6514-6525.	4.5	8
4	Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. European Urology Oncology, 2022, 5, 659-667.	5.4	8
5	Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancerâ€"Prevalence and Current Clinical Practice. Frontiers in Oncology, 2022, 12, .	2.8	3
6	Abstract 2807: HER3 is an actionable target in advanced prostate cancer. Cancer Research, 2022, 82, 2807-2807.	0.9	0
7	Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?. Cancer Imaging, 2022, 22, .	2.8	5
8	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discovery, 2021, 11, 1118-1137.	9.4	124
9	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation â€“ a Single Unit Experience. Cancer Treatment and Research Communications, 2021, 27, 100309.	1.7	2
10	Whole bodyâ€diffusion weighted imaging for the assessment of treatment response in hairy cell leukaemia: A positive first step. EJHaem, 2021, 2, 311-312.	1.0	1
11	Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. British Journal of Radiology, 2021, 94, 20200682.	2.2	8
12	The emerging role of whole-body magnetic resonance imaging in advanced prostate cancer. Minerva Urology and Nephrology, 2021, 73, 141-143.	2.5	0
13	Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC. Cancer Research, 2021, 81, CT019-CT019.	0.9	5
14	Accelerating Whole-Body Diffusion-weighted MRI with Deep Learningâ€"based Denoising Image Filters. Radiology: Artificial Intelligence, 2021, 3, e200279.	5.8	8
15	Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. Clinical Genitourinary Cancer, 2021, 19, e299-e305.	1.9	6
16	Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787). Neuro-Oncology, 2021, 23, iv10-iv10.	1.2	0
17	Early response to chemotherapy in malignant pleural mesothelioma assessed using diffusion-weighted MRI: Initial observations. JTO Clinical and Research Reports, 2021, 2, 100253.	1.1	0
18	HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research, 2021, 81, 6207-6218.	0.9	25

#	Article	IF	Citations
19	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. Cancer Imaging, 2021, 21, 67.	2.8	4
20	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 162-174.	10.7	450
21	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer, 2020, 123, 1360-1369.	6.4	10
22	Whatâ€™s New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. British Journal of Radiology, 2020, 93, 20200562.	2.2	26
23	Noise-Corrected, Exponentially Weighted, Diffusion-Weighted MRI (niceDWI) Improves Image Signal Uniformity in Whole-Body Imaging of Metastatic Prostate Cancer. Frontiers in Oncology, 2020, 10, 704.	2.8	10
24	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Nonâ€“BRCA1/2-Mutant Cancers. Cancer Discovery, 2020, 10, 1528-1543.	9.4	82
25	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2020, 38, 3195-3204.	1.6	152
26	Elucidating Durable Responses to Immune Checkpoint Inhibition. European Urology, 2020, 78, 639-641.	1.9	3
27	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. Clinical Cancer Research, 2020, 26, 4805-4813.	7.0	12
28	Genomics of lethal prostate cancer at diagnosis and castration resistance. Journal of Clinical Investigation, 2020, 130, 1743-1751.	8.2	180
29	Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phaseâ€‰II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK â€“ A16037). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097535.	3.2	2
30	Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. European Urology, 2019, 76, 469-478.	1.9	269
31	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	7.3	46
32	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. Lancet Respiratory Medicine,the, 2019, 7, 523-532.	10.7	50
33	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 529-537.	8.1	51
34	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸F-Fluoromethylcholine or ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 1253-1258.	5.0	24
35	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. Clinical Cancer Research, 2019, 25, 3830-3838.	7.0	42
36	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European Urology, 2019, 75, 184-192.	1.9	69

#	Article	IF	Citations
37	Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 548-548.	1.6	4
38	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	12.6	1,199
39	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577.	2.2	70
40	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease. Investigative Radiology, 2018, 53, 96-102.	6.2	36
41	Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. European Radiology, 2018, 28, 1687-1691.	4.5	29
42	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	12.1	59
43	Quantitative Whole-Body Diffusion-Weighted MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 479-494.	1.1	19
44	Metastasis Reporting and Data System for Prostate Cancer in Practice. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 527-542.	1.1	8
45	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discovery, 2018, 8, 1270-1285.	9.4	187
46	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 280-284.	2.3	33
47	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical Cancer Research, 2018, 24, 5585-5593.	7.0	113
48	Microstructure Characterization of Bone Metastases from Prostate Cancer with Diffusion MRI: Preliminary Findings. Frontiers in Oncology, 2018, 8, 26.	2.8	9
49	Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5024-5024.	1.6	2
50	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. Blood, 2018, 132, 3237-3237.	1.4	0
51	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. European Urology, 2017, 71, 81-92.	1.9	230
52	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 2017, 7, 1006-1017.	9.4	341
53	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. Clinical Genitourinary Cancer, 2017, 15, e801-e807.	1.9	16
54	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. Radiology, 2017, 284, 88-99.	7.3	45

#	Article	IF	Citations
55	Whole-Body MRI: Current Applications in Oncology. American Journal of Roentgenology, 2017, 209, W336-W349.	2.2	89
56	The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. BMC Cancer, 2017, 17, 456.	2.6	30
57	Rationale for Modernising Imaging in Advanced Prostate Cancer. European Urology Focus, 2017, 3, 223-239.	3.1	62
58	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283, 168-177.	7.3	81
59	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. Journal of Clinical Oncology, 2017, 35, 2503-2503.	1.6	12
60	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 2506-2506.	1.6	22
61	Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease.. Journal of Clinical Oncology, 2017, 35, 8556-8556.	1.6	10
62	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget, 2017, 8, 104430-104443.	1.8	5
63	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. Journal of Clinical Oncology, 2017, 35, 5071-5071.	1.6	0
64	Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease. PLoS ONE, 2016, 11, e0153840.	2.5	40
65	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology, 2016, 280, 151-160.	7.3	51
66	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clinical Genitourinary Cancer, 2016, 14, 485-493.	1.9	30
67	T 2 -adjusted computed diffusion-weighted imaging: A novel method to enhance tumour visualisation. Computers in Biology and Medicine, 2016, 79, 92-98.	7.0	9
68	Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience.. Journal of Clinical Oncology, 2016, 34, 2043-2043.	1.6	2
69	Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.. Journal of Clinical Oncology, 2016, 34, 2504-2504.	1.6	27
70	A phase I study of 2-hydroxyoleic acid (2-OHOA), a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including refractory high grade gliomas/glioblastomas (GBM): Updated results of the expansion.. Journal of Clinical Oncology, 2016, 34, e14086-e14086.	1.6	1
71	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. Journal of Clinical Oncology, 2016, 34, 5043-5043.	1.6	0
72	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	28.9	2,660

#	Article	IF	Citations
73	PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology, 2015, 67, 795-802.	1.9	195
74	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clinical Cancer Research, 2015, 21, 4586-4596.	7.0	171
75	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	27.0	1,796
76	Plasma AR and abiraterone-resistant prostate cancer. Science Translational Medicine, 2015, 7, 312re10.	12.4	366
77	Response evaluation in mesothelioma: Beyond RECIST. Lung Cancer, 2015, 90, 433-441.	2.0	25
78	Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study. PLoS ONE, 2014, 9, e91779.	2.5	104
79	Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. Clinical Cancer Research, 2014, 20, 5672-5685.	7.0	66
80	Tumor clone dynamics in lethal prostate cancer. Science Translational Medicine, 2014, 6, 254ra125.	12.4	298
81	Visceral Disease in Castration-resistant Prostate Cancer. European Urology, 2014, 65, 270-273.	1.9	172
82	Therapy monitoring of skeletal metastases with whole-body diffusion MRI. Journal of Magnetic Resonance Imaging, 2014, 39, 1049-1078.	3.4	99
83	Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. Journal of the National Cancer Institute, 2014, 106, dju033.	6.3	59
84	Diffusion-Weighted MR Imaging in Oncology. Current Radiology Reports, 2014, 2, 1.	1.4	4
85	A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Research, 2014, 34, 3663-8.	1.1	50
86	Competing Technology for PET/Computed Tomography. PET Clinics, 2013, 8, 259-277.	3.0	1
87	Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity. Radiology, 2012, 265, 426-436.	7.3	51
88	Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. Journal of Clinical Oncology, 2011, 29, 1271-1279.	1.6	189